| scholarly article | Q13442814 |
| P50 | author | David E. Kleiner | Q41449492 |
| P2093 | author name string | David Herion | |
| T Jake Liang | |||
| Theo Heller | |||
| Jay H Hoofnagle | |||
| Xiongce Zhao | |||
| Christopher Koh | |||
| Sasan Sakiani | |||
| Pallavi Surana | |||
| Jason Eccleston | |||
| Milica Chernick | |||
| P2860 | cites work | Cystic fibrosis | Q28250200 |
| Cirrhosis and other liver disease in cystic fibrosis | Q28660820 | ||
| Chronic liver injury induced by drugs: a systematic review. | Q30278737 | ||
| Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis | Q30401743 | ||
| Non-invasive evaluation of cystic fibrosis related liver disease in adults with ARFI, transient elastography and different fibrosis scores | Q30465393 | ||
| A single centre experience of liver disease in adults with cystic fibrosis 1995-2006. | Q33377573 | ||
| Hepatic involvement and portal hypertension predict mortality in chronic granulomatous disease | Q33379412 | ||
| Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia | Q33394303 | ||
| Nodular regenerative hyperplasia in common variable immunodeficiency | Q33405963 | ||
| Factors associated with the platelet count in patients with chronic hepatitis C. | Q33420784 | ||
| Features of Severe Liver Disease With Portal Hypertension in Patients With Cystic Fibrosis | Q33431380 | ||
| Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus | Q34044333 | ||
| Nodular regenerative hyperplasia of the liver. A review of 14 cases. | Q34418640 | ||
| AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection | Q34454310 | ||
| Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. | Q34544284 | ||
| Liver disease in children with cystic fibrosis | Q34674329 | ||
| Nodular regenerative hyperplasia: not all nodules are created equal. | Q36519149 | ||
| Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy | Q36769099 | ||
| Non-invasive evaluation of liver fibrosis using transient elastography | Q37107626 | ||
| Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease | Q37887181 | ||
| Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules | Q37928516 | ||
| Non-invasive liver elastography (Fibroscan) for detection of cystic fibrosis-associated liver disease | Q44022305 | ||
| Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease | Q44290461 | ||
| A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. | Q44527614 | ||
| Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection | Q44920531 | ||
| ARFI and transient elastography for characterization of cystic fibrosis related liver disease: first longitudinal follow-up data in adult patients | Q45669424 | ||
| [Value of transient elastography in noninvasive assessment in children's hepatic fibrosis]. | Q46009537 | ||
| ASAT/ALAT ratio provides prognostic information independently of Child-Pugh class, gender and age in non-alcoholic cirrhosis | Q46495880 | ||
| Nodular regenerative hyperplasia and severe portal hypertension in cystinosis | Q46983519 | ||
| Longitudinal Transient Elastography Measurements Used in Follow-up for Patients with Cystic Fibrosis | Q49078988 | ||
| Transient elastography in patients with cystic fibrosis. | Q51141266 | ||
| Correlation of Transient Elastography With Severity of Cystic Fibrosis-related Liver Disease. | Q51433723 | ||
| Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy | Q57651838 | ||
| Hepatic abnormalities in patients with chronic granulomatous disease | Q57908242 | ||
| Aspartate aminotransferase to platelet ratio and fibrosis-4 as biomarkers in biopsy-validated pediatric cystic fibrosis liver disease | Q60589075 | ||
| Utility of transient elastography in the non-invasive evaluation of cystic fibrosis liver disease | Q61790624 | ||
| Cystic fibrosis-associated colitis and fibrosing colonopathy | Q71749751 | ||
| Analysis of risk factors for the development of liver disease associated with cystic fibrosis | Q72274632 | ||
| Natural history of liver disease in cystic fibrosis | Q73114499 | ||
| Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group | Q77958537 | ||
| Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome | Q78560745 | ||
| Liver disease in cystic fibrosis | Q81365513 | ||
| Hepatobiliary abnormalities and disease in cystic fibrosis: epidemiology and outcomes through adulthood | Q84068608 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cystic fibrosis | Q178194 |
| P304 | page(s) | 591-601 | |
| P577 | publication date | 2017-04-19 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Adult-onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity. | |
| P478 | volume | 66 |
| Q90603976 | Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients |
| Q50145379 | Cystic fibrosis liver disease in adults: Limits of noninvasive tests of fibrosis |
| Q90575044 | Diet-Induced Dysbiosis and Genetic Background Synergize With Cystic Fibrosis Transmembrane Conductance Regulator Deficiency to Promote Cholangiopathy in Mice |
| Q92855722 | Hepatic Manifestations of Cystic Fibrosis |
| Q89727625 | Heterogeneous Liver on Research Ultrasound Identifies Children with Cystic Fibrosis at High Risk of Advanced Liver Disease: Interim Results of a Prospective Observational Case-Controlled Study |
| Q91325739 | Liver Disease in Cystic Fibrosis: Illuminating the Black Box |
| Q50042663 | Liver disease in patients with cystic fibrosis |
| Q92841151 | Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients |
| Q92267356 | Multidisciplinary Care for Cystic Fibrosis Liver Disease: Where Does the Adult Hepatologist Fit In? |
| Q91919553 | Pathophysiology of Cystic Fibrosis Liver Disease: A Channelopathy Leading to Alterations in Innate Immunity and in Microbiota |
| Q49334378 | Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease |
| Q90582997 | The Efficacy of MRI in the diagnostic workup of cystic fibrosis-associated liver disease: A clinical observational cohort study |
| Q64077819 | The emerging burden of liver disease in cystic fibrosis patients: A UK nationwide study |
Search more.